"For decades, millions of people have been advised to take aspirin to reduce their risk of experiencing a serious cardiovascular event. A daily low-dose aspirin makes blood less sticky and helps prevent heart attacks and strokes. But now a new study, presented at the world's largest heart conference, has found that clopidogrel, a commonly prescribed blood thinner, is more effective and with no extra risk."
"Their comprehensive analysis of nearly 29,000 patients with coronary artery disease (CAD) found that clopidogrel was better than aspirin in preventing serious heart and stroke events, without increasing the risk of major bleeding. CAD is the most common form of heart disease and a leading cause of death and disability globally. More than 300 million people live with CAD, including 2.3 million in the UK."
An international analysis of nearly 29,000 patients with coronary artery disease across the US, UK, Australia, Switzerland and Japan found clopidogrel superior to aspirin in preventing serious heart attacks and strokes without increasing major bleeding risk. Coronary artery disease affects more than 300 million people worldwide and often requires lifelong preventive therapy. Daily low-dose aspirin has long been prescribed to reduce cardiovascular risk by inhibiting platelet aggregation. The analysis indicates clopidogrel reduces serious cardiovascular events more effectively than aspirin and challenges aspirin's role as the default long-term antiplatelet agent for many patients with CAD.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]